



# International Journal of Innovative Research in Science Engineering and Technology (IJIRSET)

*(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)*



**Impact Factor: 8.699**

**Volume 15, Special Issue 1, January 2026**

# AI- Driven Nanotechnology in Drug Delivery

Trushal S. Singh<sup>1</sup>, Mohit M. Jadhav<sup>1</sup>, Aniket A. Singh<sup>1</sup>, Swastik R. Mishra<sup>1</sup>

Department of Pharmaceutics, Siddhis Institute of Pharmacy, (Affiliated to Dr Babasaheb Ambedkar Technological University Lonere Raigad), Nandgaon, Thane, India<sup>1</sup>

**ABSTRACT:** The combination of artificial intelligence (AI) and nanotechnology is swiftly reshaping drug delivery systems, providing extraordinary accuracy, customization, and therapeutic effectiveness. AI enhanced nanotechnology allows for the systematic design, optimization, and live tracking of nanocarriers, improving the targeted transport of medications while reducing overall toxicity. Machine learning algorithms are crucial in forecasting nanoparticles' behaviors, including their distribution, drug release rates, cellular absorption, and toxicity profiles. Additionally, deep learning techniques expedite the selection of ideal nanomaterial formulations and surface modifications, significantly cutting down on experimental efforts and development time. These innovations lead to advanced nanocarriers with responsive drug release and better stability. Despite advancements, the intersection of AI and nanotechnology brings forth significant safety issues. Nanomaterials exhibit distinctive physicochemical characteristics that could result in unexpected toxic effects, immune reactions, and bioaccumulation. Even though AI-driven predictive models are useful, they may carry biases from their training data, which could compromise the accuracy of safety evaluations. Additionally, the scarcity of long-term toxicity information, difficulties in in-vivo extrapolation, and the intricate interactions of nanocarriers in biological environments hinder thorough risk assessment. The incorporation of AI also raises concerns about transparency, reproducibility, and validation of algorithms, complicating the regulatory scrutiny of AI-developed nanomedicines.

Global regulatory frameworks are progressing but still display inconsistencies in addressing AI-powered nanotechnologies. Organizations like the FDA and EMA focus on risk-based evaluations, comprehensive data validation, and algorithm transparency. Nevertheless, there is still a scarcity of standardized protocols for the design, preclinical testing, and life cycle management of AI-based nanomedicine. The evolving nature of machine learning models introduces further hurdles for regulatory approval, necessitating ongoing oversight, version management, and thorough documentation of updates. Additionally, the absence of unified international standards complicates uniform safety and quality assessments across different regions. This article thoroughly explores the latest advancements in AI-supported nanocarrier technology, addresses new safety issues linked to sophisticated nanomaterials and algorithm-based decision-making, and evaluates existing regulatory viewpoints in this fast-changing area. By combining discussions of technological progress with ethical, safety, and policy implications, it emphasizes the necessity for cohesive regulatory systems, enhanced datasets for AI development, and cross-disciplinary cooperation to facilitate the secure and effective application of AI-enhanced nanotechnologies in healthcare.

**KEYWORDS:** Artificial Intelligence (AI), Nanotechnology, Nanomedicines, Smart Nanocarriers, Targeted Drug Delivery.

## I. INTRODUCTION

Nanotechnology has become a groundbreaking approach in the field of medicine, especially in the area of drug delivery. Its effectiveness stems from the creation of nanoscale carriers that improve drug solubility, stability, targeted administration, and controlled release. In recent years, various types of nanoparticles—including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and nanoemulsions—have been utilized to enhance therapeutic outcomes while minimizing systemic side effects. These innovative systems facilitate localized drug accumulation and offer novel treatment options for complex ailments such as cancer, infections, and neurological conditions<sup>1</sup>.

At the same time, advancements in artificial intelligence (AI) technologies—such as machine learning, deep learning, and extensive data analysis—have swiftly progressed in the healthcare sector. AI applications are capable of examining large datasets, forecasting disease trends, optimizing treatment approaches, and expediting biomedical research. In the

context of drug delivery, AI applications are being studied to refine nanoparticle design, anticipate interactions between drugs and nanocarriers, fine-tune formulation parameters, and simulate biological responses<sup>2</sup>.

The integration of AI with nanotechnology creates a compelling case for developing more precise, effective, and personalized drug delivery systems. AI can streamline formulation development by minimizing trial-and-error, improving targeting precision, and enabling real-time tracking of nanocarrier activities within the body. This merging of technologies has the potential to accelerate development timeframes and enhance the clinical application of nanomedicines<sup>3</sup>.

The intersection of artificial intelligence (AI) and nanotechnology is revolutionizing pharmaceutical development, transforming the design, optimization, and delivery of therapeutics. This synergy uses computational capabilities to address conventional drug delivery challenges, facilitating the development of responsive nanocarriers that adjust to physiological states while ensuring precise targeting. By fusing machine learning techniques with advanced nanotechnology, scientists can now create multifunctional nanomedicines that enhance efficacy and reduce systemic toxicity through tailored delivery methods. This review explores the combined use of AI and nanotech in drug delivery systems, covering key principles, innovations, disease applications, regulatory considerations, and avenues for clinical use<sup>4,5,6</sup>.


## II. FUNDAMENTALS OF NANOTECHNOLOGY IN DRUG DELIVERY

Over the last twenty years, advances in nanotechnology have greatly impacted medicine, leading to the creation of various nanocarriers designed to tackle specific medical challenges. Nanotechnology focuses on creating and utilizing materials at the nanoscale (1–100 nm) to enhance the effectiveness of drug delivery systems by improving factors such as solubility, stability, targeting accuracy, and the controlled release of therapeutic substances. In this context, various nanocarriers—including liposomes, polymeric nanoparticles, dendrimers, micelles, nanoemulsions, and inorganic nanoparticles—are developed to safeguard drugs from breakdown, extend their presence in the bloodstream, and accurately transport them to affected areas.

### 2.1 Types Of Nanocarriers

#### 1. Liposomes


Among the earliest and most well-established of these systems are liposomes, which consist of phospholipid bilayers. These spherical structures are capable of encasing both water-soluble and lipid-soluble drugs, providing notable biocompatibility while minimizing hemolytic toxicity in comparison to unencapsulated medications. Their clinical viability is highlighted by formulations like liposomal doxorubicin (Doxil), which has shown significant reductions in cardiotoxicity while still being effective against cancer<sup>7</sup>.



**Figure 1.** Liposomes (Rumiana Tenchov, Robert Bird, Allison E. Curtze, and Qiongqiong Zhou. ACS Nano 2021, Lipid Nanoparticles – From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement, Publication Date: June 28, 2021 <https://doi.org/10.1021/acsnano.1c04996>)

### 1. Polymeric Nanoparticle


Polymeric nanoparticles, especially those made from poly(lactic-co-glycolic acid) (PLGA), offer enhanced stability and regulated drug release compared to liposomes. Their properties can be adjusted to achieve targeted drug loading rates and release patterns by altering the polymer's composition and its molecular weight. Research comparing these nanoparticles found that they could achieve docetaxel loading efficiencies of around  $62.34 \pm 1.5\%$ , demonstrating their utility in various therapeutic applications<sup>8</sup>.



**Figure 2.** Polymeric Nanoparticle (Zielińska, A., Carreiró, F., Oliveira, A. M., Neves, A., Pires, B., Venkatesh, D. N., Durazzo, A., Lucarini, M., Eder, P., Silva, A. M., Santini, A., & Souto, E. B. (2020). Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. *Molecules*, 25(16), 3731. <https://doi.org/10.3390/molecules25163731>)

### 1. Dendrimers


Dendrimers are another innovative form of nanocarrier. These branched macromolecules have a dendritic structure that allows for precise control over their size and shape. Their numerous functional groups on the surface can accommodate multiple drug molecules and facilitate the attachment of targeting ligands, making them especially useful for combination therapies and personalized medicine. However, they pose challenges in formulation due to their lower drug encapsulation efficiency, with approximately  $28.26 \pm 1.74\%$  for docetaxel<sup>9</sup>.



**Figure 3.** Dendrimer (Santos, A., Veiga, F., & Figueiras, A. (2020). Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications. *Materials*, 13(1), 65. <https://doi.org/10.3390/ma13010065>)

### 1. Nanoemulsions And Metallic Nanoparticles

Nanoemulsions and metallic nanoparticles, such as those made from gold, silver, and iron oxide, present unique benefits in imaging and photothermal treatment applications. Gold nanoparticles are particularly well-researched due to their plasmonic properties and potential use in immunoassays, while silver nanoparticles are recognized for their natural antimicrobial properties. Moreover, quantum dots—semiconductor nanoparticles with optical properties that vary with size—enable simultaneous drug delivery and real-time fluorescent imaging, paving the way for theranostic uses<sup>10,11</sup>.



**Figure 4.** Nanoemulsion (Patel MR, Patel RB, Thakore SD. Nanoemulsion in drug delivery. In: Patel MR, editor. Applications of Nanocomposite Materials in Drug Delivery. Woodhead Publishing; 2018. P. 667–700. Doi:10.1016/B978-0-12-813741-3.00030-3.)


## 2. Mechanisms of Nanocarrier-Mediated Drug Delivery

The methods by which nanocarriers deliver drugs can be divided into three primary categories: passive targeting, active targeting, and stimuli-responsive systems, each of which has unique strengths and weaknesses. Passive targeting takes advantage of the enhanced permeability and retention (EPR) effect, where nanoparticles accumulate preferentially in tumor tissues due to the presence of leaky blood vessels and impaired lymphatic drainage. This effect is particularly significant in cancerous tissues, where irregular blood vessel formation creates endothelial gaps of 100-1000 nm, allowing nanoparticles sized between 50 and 200 nm to escape into the tumor while being trapped in healthier tissues with tighter endothelial connections. Modifications to nanoparticle surfaces, such as attaching polyethylene glycol (PEG) (a process known as PEGylation), enhance circulation times by inhibiting opsonization, which is the marking of particles for clearance by the reticuloendothelial system (RES)<sup>12,13,14</sup>.

Active targeting utilizes specific ligands, such as antibodies, peptides, or aptamers, on the surfaces of nanoparticles to recognize and bind to receptors that are overexpressed in diseased cells. This method increases the specificity and effectiveness of drug delivery compared to passive targeting, although it adds complexity to the formulation. The choice of ligands and their optimization are crucial for enhancing internalization rates and therapeutic outcomes<sup>15</sup>. Stimuli-responsive systems are a novel approach where drug release is prompted by targeted biological or environmental signals. pH-sensitive nanoparticles can respond to the acidic conditions typical of tumors or endosomal compartments, altering their structure to release drugs within target cells. Temperature-sensitive polymeric micelles change from soluble structures to nanoparticles at specific physiological temperatures, enabling drug encapsulation or release. Systems that respond to enzymes found at disease sites, light, or magnetic fields allow for finely-tuned control of therapeutic delivery<sup>16,17,18</sup>.

## 3. ROLE OF ARTIFICIAL INTELLIGENCE IN NANOMEDICINE

The incorporation of machine learning into nanoparticle design has revolutionized the discovery paradigm, moving away from traditional trial-and-error methods toward predictive computational techniques. A notable illustration of this transformation is seen in the integration of machine learning with high-throughput microfluidics for the synthesis of silver nanoparticles. Researchers established a dual-phase machine learning model that combines Bayesian optimization and deep neural networks (DNNs) to efficiently synthesize nanoparticles with specific optical characteristics. By evaluating just 120 chemical conditions, this unified algorithmic approach achieved the desired absorbance spectra much more quickly than conventional techniques, and verification through transmission electron microscopy confirmed that nanoparticles were synthesized accurately within the targeted size ranges.



**Figure 5.** Role Of Artificial Intelligence In Nanomedicines (Sarah I Mazi, Abdulahi M Hassen, Fahad A Alrashed, Fatiha M. Benslimane, Nura A Mohamed. Artificial Intelligence-Nanomedicine Interface: Today's Theory Tomorrow's Technology. Archives of Clinical and Biomedical Research. 7 (2023): 635-641.)

## 1.2. Machine Learning In Nanoparticle Design

Machine learning techniques facilitate the prediction of essential nanoparticle attributes such as dimensions, morphology, surface charge, hydrophobicity, and drug encapsulation effectiveness based on synthesis parameters. These predictive abilities enhance formulation development, allowing scientists to methodically investigate extensive parameter ranges without the need for an equivalent number of physical experiments. Effective feature engineering is crucial in this context, necessitating the careful selection and extraction of relevant physicochemical traits that reflect nanoparticle characteristics and their interactions with biological systems.

Recent innovations have showcased machine learning's capacity not only to forecast nanoparticle properties but also to derive mechanistic insights into structure-property relationships. For example, the use of SHAP (Shapley Additive exPlanations) values highlighted that concentrations of silver nitrate and quantities of seed particles were pivotal in influencing nanoparticle optical properties, providing valuable design guidelines for future synthesis endeavors<sup>19,20</sup>.

## 1.2. AI-Enhanced Toxicity Assessment And Biocompatibility Prediction

Artificial intelligence holds significant potential in nanomedicine, particularly in accurately forecasting the toxicity of nanoparticles without the need for extensive animal testing. This advancement addresses both ethical and practical issues related to nanosafety research. Traditional machine learning techniques, such as Random Forest and Support Vector Machines (SVM), have shown reasonable effectiveness in predicting nanotoxicity, with Random Forest algorithms consistently outperforming their counterparts across various studies. Recently, the rise of automated machine learning (autoML) platforms has considerably enhanced the reliability and accuracy of these predictions. A detailed comparative analysis of autoML platforms like Vertex AI, Azure, and Dataiku against traditional machine learning methods showcased a marked improvement in performance. AutoML models achieved an average accuracy between 0.91 and 0.96, with a standard deviation of 0.01 to 0.03, surpassing the traditional models that had accuracy levels of 0.80 to 0.92 and standard deviations of 0.02 to 0.04. Notably, autoML platforms also significantly enhanced F1 scores, which are crucial for evaluating imbalanced classes of toxic versus non-toxic materials, with mean improvement ranging from minimal to considerable<sup>21,22</sup>.

These advancements are crucial not just for statistical purposes but also for health safety. Poor recall (sensitivity) in predictive models could lead to dangerous nanoparticles being inaccurately labeled as safe, posing risks to public health. On the other hand, low precision may incorrectly categorize harmless nanomaterials as hazardous, limiting their

beneficial uses. The substantial reduction in variability of performance facilitated by auto ML platforms results in more reliable models that can effectively assist in regulatory decisions.

For nanotoxicity prediction, data inputs generally include physicochemical characteristics such as size, surface area, zeta potential, composition, and aggregation behavior, alongside biological factors like cell line type, exposure levels, and tissue types. Analysis of these features indicates that cell line, exposure level, and tissue type are the most critical factors influencing cell mortality. Insights gained through machine learning can help prioritize formulation parameters to improve safety outcomes<sup>23</sup>.

### **1.2. AI-Driven Pharmacokinetic And Pharmacodynamic Modeling**

Reimagining the biodistribution and systemic exposure of nanoparticles is a vital area where AI-enhanced modeling can make a significant impact. A novel multi-view deep learning framework has been developed, which incorporates essential characteristics of nanoparticles, such as size and charge, by utilizing cross-attention mechanisms. This context-aware feature selection enriches generalization capabilities even when experimental data is sparse. This technique stands in stark contrast to traditional data-driven approaches, which often falter in identifying meaningful insights from small, diverse datasets. By employing an ensemble learning methodology that merges deep learning with algorithms like XGBoost and Random Forest, this framework achieves markedly better performance than standalone models through the use of combined predictive strengths<sup>24</sup>.

Integrating machine learning with physiologically-based pharmacokinetic (PBPK) modeling marks a significant evolution in prediction accuracy. PBPK models consist of various tissue compartments that reflect key physiological structures, facilitating the prediction of how drugs are distributed, metabolized, and eliminated across organs. When applying ML-derived physicochemical attributes as inputs into PBPK models, these predictive outcomes effectively represent the biphasic behavior of plasma exposure, targeting tissue distribution, and clearance processes. Notably, parameters generated by machine learning yield predictions that are either on par with or exceed those obtained from experimental data, as ML methodologies help minimize the variability often associated with experimental results<sup>25</sup>.

### **1.2. AI For High-Throughput Screening And Material Discovery**

The combination of microfluidic techniques for nanoparticle creation with machine learning optimization has developed into a significant method for speeding up the discovery of nanomaterials. In a notable approach, scientists integrated microfluidic processes, advanced imaging technologies, and machine learning in a cyclical system. Here, active learning algorithms determine which nanoparticle formulations to evaluate next based on model outcomes. This method minimizes the number of experiments needed to produce optimized nanoparticles with specific biological interactions by focusing on the most significant parameter combinations.

Moreover, the application of artificial intelligence in microfluidics also leads to self-operating nanoparticle synthesis systems. These smart microfluidic devices use machine learning models (such as decision trees, random forests, and deep learning networks) for precise real-time predictions of nanoparticle characteristics based on synthesis parameters, achieving remarkable accuracy in estimating properties like hydrodynamic diameter, polydispersity index, and encapsulation efficiency. These closed-loop systems continuously adjust the synthesis conditions, allowing for the production of highly controlled and reproducible nanoparticles at unprecedented scales<sup>26,27</sup>.

## **2. AI-DRIVEN SMART NANO-DRUG DELIVERY SYSTEMS**

The strategic development of targeted nanoparticles increasingly depends on AI-driven analysis to identify the best ligand-receptor pairs and enhance target selectivity. AI technologies can evaluate extensive databases of potential ligands, estimating their binding strength, efficiency of cellular uptake, and unintended interactions, all informed by molecular structures and the expression of disease-related biomarkers. Machine learning approaches that examine the characteristics of the tumor microenvironment (such as pH, oxygen levels, and immune cell presence) can forecast the behavior of targeted nanoparticles in these scenarios, supporting the preclinical identification of the most suitable formulations for distinct patient groups.

Tailored targeting for individual patients emerges as an innovative avenue where AI utilizes personal genomic, proteomic, and imaging data to propose custom nanoparticle designs and drug combinations. Integrated computational platforms that analyze multi-omics information can pinpoint specific biomarkers in each patient's cancer, anticipate

which surface modifications on nanoparticles will achieve the most effective targeting of those unique epitopes, and provide predictions of therapeutic outcomes with much greater precision compared to generic methods<sup>28,29</sup>.

### **1.2. AI-Controlled Stimuli-Responsive Nanocarriers**

The creation of multi-responsive nanoparticles that react to various physiological triggers at once is a field where AI greatly enhances the optimization process. Utilizing deep learning algorithms allows for the prediction of how dual-responsive systems—such as polymeric nanoparticles responsive to temperature and pH—will function in the complex environments encountered during circulation and tissue infiltration. Polymer nanoparticles engineered to respond to both temperature and pH with transition temperatures between 27–31°C, which align with physiological conditions, showed about 40% hydrolysis of acetal groups in acidic environments (pH 5.0) that resemble tumor microenvironments. This reaction leads to a loss of thermoresponsive characteristics and causes the nanoparticles to disintegrate, thereby releasing therapeutic agents.

Additionally, machine learning can ascertain the most effective sensitivities for multi-stage responsive systems, where successive physiological signals work together to dismantle nanoparticle defenses and release medication in a precisely timed sequence. This advanced capability allows for the design of nanoparticles that preserve drug stability during circulation, prevent premature release in healthy tissues, and only initiate drug release when in contact with disease-specific environments.

### **1.2. AI-Enabled Nanosensors and Theranostic Platforms**

Theranostic nanoparticles that diagnose and treat illnesses simultaneously showcase a groundbreaking area where AI significantly enhances functionality. AI-enhanced nanosensor platforms can continuously track vital signs (such as glucose, pH levels, and oxygen deficiency), offering adaptive feedback that regulates drug release in real-time. This shift from a static drug delivery method to an active, responsive therapeutic approach reflects a major advancement in how treatments are tailored to evolving medical conditions.

Furthermore, AI techniques can process multispectral imaging data from theranostic nanoparticles to detect disease markers with greater precision than traditional methods and forecast the best therapeutic interventions. The combination of AI and nanoplasmonic biosensors allows for the simultaneous identification of multiple cancer biomarkers, promoting early detection of diseases while also providing targeted treatments<sup>30</sup>.


## **2. APPLICATIONS IN MAJOR DISEASE AREAS**

### **1.3. Cancer**

Cancer is the leading field for the application of AI-enhanced nanomedicine, with numerous clinical trials currently in progress. AI technologies refine the development of nanoparticles aimed at tumors by interpreting patient-specific genomic, transcriptomic, and proteomic data to anticipate which surface-modified nanoparticles will most effectively accumulate in individual tumors. Machine learning algorithms can assess how nanoparticles will respond to the tumor microenvironment, allowing for the selection of nanoparticles that are sensitive to specific conditions such as pH levels, oxygen availability, and enzyme expression particular to each tumor.

Additionally, computational modeling tools predict how nanoparticles distribute within tumors, estimating accumulation trends, drug release patterns, and interactions with immune cells associated with the tumor, thus forecasting therapeutic success prior to clinical application. For instance, companies like Insilico Medicine have created AI-driven systems that design nanoparticles for cancer treatment by examining biological information and simulating drug activities in the tumor environment. Using machine learning to optimize the size, shape, and makeup of nanoparticles has led to the development of formulations that can effectively target cancer cells without being detected by the immune system.


Furthermore, the incorporation of AI in combinatorial drug design through nanoparticle systems allows for the enhancement of multi-drug therapies. Here, machine learning can identify synergistic drug combinations, the most effective drug ratios, and the ideal sequence for drug administration to enhance cancer-fighting capabilities while reducing unwanted side effects. The CURATE.AI platform illustrates this method by facilitating personalized adjustments to chemotherapy regimens, based on ongoing monitoring of pharmacodynamic responses<sup>28,29</sup>.



**Figure 6.** Cancer (Alrushaid, N., Khan, F. A., Al-Suhaimi, E. A., & Elaissari, A. (2023). Nanotechnology in Cancer Diagnosis and Treatment. *Pharmaceutics*, 15(3), 1025. <https://doi.org/10.3390/pharmaceutics15031025>)

### 1.2. Neurological Disorders And Blood-Brain Barrier Penetration

The blood-brain barrier (BBB) is a selective barrier consisting of specialized endothelial cells connected by tight junctions, which poses a major obstacle for delivering drugs to the central nervous system (CNS). In conditions like Alzheimer’s and Parkinson’s diseases, the BBB becomes dysfunctional, displaying reduced expression of tight junction proteins such as claudin-5, ZO1, occludin, and VE-cadherin, along with degeneration of pericytes and increased leakage of immunoglobulins around blood vessels. Nanoparticles specifically designed for these altered BBB conditions, enhanced through AI optimization, have shown improved penetration capabilities compared to those tailored for a healthy BBB.



**Figure 7.** Neurological Disorders (Dhariwal R, Jain M, Mir YR, Singh A, Jain B, Kumar P, Tariq M, Verma D, Deshmukh K, Yadav VK and Malik T (2025) Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology. *Front. Med.* 12:1522223. Doi: 10.3389/fmed.2025.1522223)

Nanoparticles enhanced with peptide sequences that facilitate BBB crossing, including AP-2 and D-peptides, exhibit varying effectiveness depending on the state of the brain—normal or diseased. Machine learning techniques contribute to predicting the best combinations of peptides for specific neurological disorders. In studies related to Alzheimer’s disease, D-peptide modifications outperformed receptor-mediated targeting methods within affected brain models, illustrating how AI-driven customization according to particular pathological states can enhance drug delivery. Moreover, nanoconjugates featuring targeting sequences have successfully transported functional microRNA and antisense oligonucleotides into neurons in Alzheimer’s disease models, leading to therapeutic alterations in molecular pathways associated with neurodegeneration.


Deep learning strategies enable the prediction of BBB permeability across various molecular designs and nanoparticle types, streamlining the evaluation of delivery vehicles without the necessity for exhaustive experimental investigations on BBB penetration. These computational methodologies significantly expedite the creation of treatments for conditions such as stroke, epilepsy, glioblastoma, and other CNS disorders where overcoming the BBB is a critical factor for effective therapy<sup>31,32</sup>.

### 1.2. Infectious Disease Treatment and Prevention

Nanoparticle-driven vaccines are gaining traction as highly effective tools for preventing infectious diseases, with the COVID-19 pandemic boosting their clinical advancement. Lipid nanoparticles (LNPs) that encapsulate mRNA vaccines demonstrate enhanced immunogenicity in comparison to standalone mRNA or protein subunit vaccines. In preclinical studies, LNP-based COVID-19 vaccines have been shown to produce neutralizing antibody titers that are 10 to 50 times higher than those from traditional vaccine approaches.

Formulations of AI-optimized nanoparticle vaccines enhance immune response through a computational approach that tailors nanoparticle size, surface charge, lipid makeup, and arrangement of payload to optimize the presentation of antigens to antigen-presenting cells and improve trafficking to lymph nodes. Machine learning algorithms can identify the ideal features of nanoparticles to stimulate both antibody (humoral) and T-cell (cellular) immune responses against a range of pathogens.

In addition to their role in vaccination, nanosensors play a crucial role in the early detection of pathogens via multiplexed biosensing for pathogen biomarkers. Lateral flow assays using gold nanoparticles provide rapid and sensitive point-of-care detection of the SARS-CoV-2 nucleocapsid protein, enabling early identification of infected individuals prior to the onset of symptoms. Moreover, polymeric nanoparticles coated with macrophage membranes function as biological traps, capturing viral particles and obstructing their entry into cells; studies in hamsters have shown that these nanoparticles significantly lower the viral load in the lungs by inhibiting SARS-CoV-2 infectivity in a dose-dependent manner<sup>33,34,35</sup>.




**Figure 8.** Infectious Disease Treatment (Ex: COVID-19) (Vu MN, Kelly HG, Kent SJ, Wheatley AK. Current and future nanoparticle vaccines for COVID-19. *EBioMedicine*. 2021 Dec;74:103699. Doi: 10.1016/j.ebiom.2021.103699. Epub 2021 Nov 19. PMID: 34801965; PMCID: PMC8602808)

## 1.2. Cardiovascular And Metabolic Disease Management

Atherosclerosis, high blood pressure, and metabolic disorders are new areas where AI-enhanced nanoparticles are meeting crucial medical needs. The use of nanoparticles for delivering anti-inflammatory and lipid-adjusting drugs to plaques in arteries takes advantage of the fact that such lesions show a specific increase in vascular permeability, allowing for the accumulation of appropriately sized nanoparticles. In preclinical trials, lipid-based nanoparticles loaded with Paclitaxel reduced the size of atherosclerotic lesions by 65%, highlighting the promise of nanoparticle therapies for reducing plaque.

Furthermore, machine learning algorithms that analyze cardiovascular imaging (including CT, MRI, and ultrasound) can forecast how individual patients will react to nanoparticle therapies, allowing for the precise selection of the most suitable formulations prior to treatment. AI systems also enhance the delivery of substances like nitric oxide, vasodilatory peptides, and anti-inflammatory medications to the endothelium in at-risk vascular areas, focusing on treating the root causes of hypertension and atherosclerosis rather than just alleviating symptoms.

In managing diabetes, nanoparticles guided by AI facilitate the tailored release of insulin in response to rising glucose levels. These insulin-loaded nanoparticles are designed to emit insulin in amounts corresponding to blood sugar levels, offering better physiological control compared to traditional insulin injections. Machine learning can also predict individual patient insulin sensitivity, leading to the custom design of nanoparticle formulations for more effective metabolic management<sup>36,37</sup>.



**Figure 9.** Cardiovascular And Metabolic Disease Management (Pang, A. S.-R., Dinesh, T., Pang, N. Y.-L., Dinesh, V., Pang, K. Y.-L., Yong, C. L., Lee, S. J. J., Yip, G. W., Bay, B. H., & Srinivasan, D. K. (2024). Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis. *Molecules*, 29(12), 2873.

<https://doi.org/10.3390/molecules29122873>

## 2. INTEGRATION WITH EMERGING TECHNOLOGIES

**AI-Enhanced CRISPR Gene Delivery Systems.** The combination of artificial intelligence and CRISPR-Cas9 gene editing through nanoparticle delivery is pushing the boundaries of gene therapy, with computational advancements tackling significant obstacles. AI-driven algorithms create optimized nanoparticle vectors capable of effectively carrying multiple CRISPR elements (such as the Cas9 protein or plasmid and single guide RNA) without compromising their biological function. Utilizing machine learning, these models can suggest optimal surface modifications for targeting specific cell types, taking into consideration factors like tissue accessibility, cellular uptake processes, and the need for endosomal escape.

Responsive polymer nanocarriers that include CRISPR plasmids exhibit AI-enhanced responses to the conditions of the tumor microenvironment (like mildly acidic pH and enzyme activity), facilitating precise delivery to cancer cells while minimizing unintended genome alterations in healthy tissues. Additionally, the use of gold nanoparticles for CRISPR delivery (known as CRISPR-Gold technology) allows for fine-tuned control over dosing and decreases off-target editing through AI-enhanced surface modifications. Clinical trials have shown knockout rates exceeding 80% for genes

associated with diseases, resulting in about a 77% reduction in tumor growth in models of triple-negative breast cancer<sup>38</sup>.

### **1.2. AI-Guided 3D Bioprinting And Microfluidic Nanoparticle Synthesis**

The combination of artificial intelligence with 3D bioprinting and microfluidic technologies allows for the creation of intricate, personalized tissue models that incorporate nanoparticle drug delivery systems. Through machine learning algorithms, the parameters for 3D bioprinting—such as nozzle temperature, extrusion pressure, and printing speed—are fine-tuned to produce high-resolution, multi-material constructs with an accurate spatial distribution of therapeutic nanoparticles. These AI-enhanced bioprinted tissues closely mimic human physiological structures compared to conventional animal models, thereby advancing the fields of preclinical drug testing and the development of personalized medicine.

Furthermore, microfluidic systems that utilize AI optimization facilitate the manufacture of monodisperse nanoparticles with tightly regulated size, composition, and surface characteristics, aligning with clinical production standards. The incorporation of real-time analytical techniques, like spectroscopy and imaging, alongside machine learning frameworks establishes closed-loop control systems that ensure consistent quality of nanoparticles throughout production cycles. Innovative manufacturing methods, such as coaxial turbulent jet mixing and particle replication in non-wetting templates (known as PRINT technology), are optimized via machine learning to ensure industrial-scale output with the batch consistency necessary for meeting regulatory standards<sup>39,40,41</sup>.

### **1.2. Internet Of Nanothings (Iont) For Real-Time Monitoring**

The Internet of Bio-Nanothings (IoBNT) is an innovative framework that integrates nanosensors, nanodevices, and molecular communication alongside internet connectivity. This system facilitates instantaneous monitoring and management of drug delivery within the body. Nanoscale devices positioned within tissues can detect local physiological metrics, transmit findings through molecular signaling across intra-body nanonetworks, share data with external networks through bio-cyber interfaces, and initiate programmed actions such as drug synthesis or release.

Artificial Intelligence algorithms help navigate the intricate communication between various nanodevices while fine-tuning drug release based on perceived physiological changes. By employing compartmental models and ligand-receptor binding dynamics, it is possible to forecast the impact of drug deliveries controlled by nanodevices on targeted cell groups, while limiting interactions with surrounding healthy cells. This model signifies a substantial transition from fixed drug release methods to a more dynamic, condition-adaptive therapeutic delivery system guided by AI-managed nanosensor networks<sup>42,43</sup>.

## **2. CHALLENGES AND LIMITATIONS**

### **1.2. Data Related Barriers**

Data-Related Barriers and Standardization Issues are although there have been remarkable advancements, notable challenges hinder the widespread adoption of AI-based nanomedicine. A major issue is the limited availability and variety of high-quality, standardized datasets on the toxicity and efficacy of nanomaterials. Differences in experimental methodologies (such as synthesis techniques, characterization methods, and exposure conditions), the choice of cell lines, endpoint definitions, and reporting standards further complicate the creation of cohesive datasets necessary for training machine learning models. This variability leads to systemic biases and restricts the generalizability of the models—algorithms that perform well on one dataset often struggle on independent test datasets obtained from different research laboratories<sup>44,45</sup>.

Furthermore, the demand for explainable AI (XAI) complicates the process of model development. While certain black-box machine learning models may achieve high levels of predictive accuracy, they often lack clear explanations for their outcomes, which can hinder clinical acceptance and regulatory approval. Regulatory bodies are increasingly requiring models to be transparent and interpretable, clearly illustrating how input factors influence predictions, which calls for the creation of XAI strategies that strike a balance between accuracy in predictions and comprehensibility for users<sup>46,47</sup>.

### **1.2. Technical Limitations And Model Generalization**

The complexity of nanoparticle interactions within biological systems greatly surpasses what current computational models can accurately explain. These nanoparticles navigate ever-changing environments characterized by fluctuating

pH levels, varying enzyme concentrations, diverse cellular densities, and differing immune response scenarios. This variability goes beyond the static conditions under which most training data is gathered. Consequently, machine learning models, which are often based on constrained datasets, find it difficult to predict nanoparticle behavior in the context of the wide range of patient genetics, disease conditions, and physiological states.

Our understanding of the structure-function relationships in nanoparticles is still lacking, which hinders AI systems from making predictions beyond the confines of their training data. While machine learning algorithms are adept at uncovering patterns in available datasets, they fall short when it comes to forecasting new behaviors that lie outside those data ranges. This constraint is particularly significant when it comes to predicting long-term biocompatibility, potential accumulation in unintended organs, or interactions with newly emerged target molecule variants<sup>48</sup>.

### **1.2. Ethical, Safety, And Regulatory Challenges**

The regulatory landscape for nanomedicines powered by AI is still in its early stages and varies significantly from one jurisdiction to another. Key issues regarding the classification of AI-enhanced nanoparticles—such as whether they should be treated as drugs, biologics, devices, or hybrid products—remain largely unanswered by regulatory bodies. The evolving and adaptive characteristics of AI systems pose challenges for regulation, as algorithms that improve over time disrupt conventional pre-market approval processes that are typically designed for drugs with fixed properties.

The FDA's 510(k) process, which is commonly used for medical device approvals, is inadequate for technologies that utilize AI and evolve continuously after market entry, creating a conflict between the pace of innovation and the need for regulatory control. While regulatory agencies acknowledge these difficulties, they do not yet agree on effective management strategies, timelines for approval, or monitoring practices for AI-based nanomedicines after they hit the market.

Concerns regarding nanotoxicity and the long-term safety of these medicines are not fully understood. Although advancements have been made in predicting acute toxicity, further investigation is needed into chronic accumulation, risks of genotoxicity, potential for cancer development, and effects on organ function after prolonged exposure to nanoparticles. The evaluation of risks versus benefits for therapies involving nanoparticles must consider manufacturing inconsistencies, the likelihood of unintended accumulation in sensitive organs (such as the liver, kidneys, spleen, and brain), and the variability in individual patient immune responses and metabolic rates.

Ensuring transparency and accountability in the design of AI-driven nanomedicines is vital for gaining clinical trust. Both healthcare professionals and patients must grasp how AI systems choose specific nanoparticle designs, the data underpinning predictions, and the rationale behind recommended formulations. This calls for the creation of robust explainable AI (XAI) frameworks tailored to clinical settings<sup>49,50</sup>.

## **III. FUTURE PROSPECTS AND EMERGING DIRECTIONS**

The future of artificial intelligence systems is expected to integrate generative neural networks, such as generative adversarial networks and variational autoencoders, to autonomously create optimized nanoparticles without needing explicit prior understanding of the relationships between their structures and properties. By utilizing conditional variational autoencoders (cVAEs) trained on either synthetic or real nanoparticle datasets, these systems can produce multiple viable nanoparticle designs that meet specific target properties, thus offering researchers a range of options that balance the accuracy of predictions with manufacturability. This generative approach signifies a significant shift from traditional single-solution optimization to a focus on exploring solution spaces, allowing researchers to identify designs that cater to various competing goals at the same time.

Inverse design techniques that utilize gradient-based optimization on established generative neural networks will facilitate the automated discovery of nanoparticle structures that exhibit remarkable functional characteristics. When applied to upconverting nanoparticles, these techniques revealed structures predicted to have a 6.5 times greater emission efficiency than any materials found in the training datasets, demonstrating the exceptional extrapolative ability of well-designed generative models<sup>51</sup>.

Digital twin technology involves the creation of detailed virtual models of biological systems and nanoparticles, allowing for computational testing of therapies prior to their experimental or clinical use. By integrating molecular

## International Journal of Innovative Research in Science, Engineering and Technology

International Conference on Emerging Technologies and Pharmaceutical Research (ICETPR 2026)

17–18 January 2026

Indala College of Engineering, Polytechnic & Pharmacy, Kalyan, MH, India

[Volume 15, Special Issue 1, January 2026]

dynamics simulations, quantum mechanics, and machine learning, digital twins can forecast the behavior of nanoparticles in various tissue environments, effectively modeling aspects such as drug release rates, cellular interactions, and overall treatment effectiveness with great accuracy. Researchers at the University of California San Diego have shown that these models can reliably predict the delivery of cancer medications, aiding in preclinical trials to enhance nanoparticle designs and dosage strategies.

Patient-specific digital twins, which amalgamate individual genomic, proteomic, imaging, and physiological information, pave the way for truly personalized healthcare. This approach allows for the computational optimization of nanoparticle treatments and strategies before they are administered. These systems will dynamically incorporate feedback from patient responses to therapies, thereby continuously updating the digital models and refining treatment recommendations in real time.

Future medical treatments are set to utilize closed-loop systems that leverage AI-connected nanosensors for the ongoing observation of disease indicators and bodily functions. These systems will facilitate real-time modifications to drug delivery speeds and targeting techniques. Nanodevices, either implanted or circulating within the body, will be outfitted with biosensing technology that allows for real-time feedback, enabling personalized treatment adjustments without the need for frequent medical procedures. This advancement signifies the pinnacle of precision medicine—therapies that are genuinely adaptive and consistently respond to each patient’s unique physiology and health conditions.

Next-generation AI technologies will combine data from genomics, transcriptomics, proteomics, imaging, biosensors, and wearable devices to create detailed disease profiles for patients, guiding the development of nanoparticles and treatment options. By employing machine learning to analyze these diverse datasets, new biomarkers that forecast treatment responses will be uncovered, allowing for the selection of nanoparticle designs that maximize clinical efficacy for each patient. This approach marks a significant transition from a generalized treatment strategy to one that precisely addresses the unique pathophysiology of individuals with tailored therapeutic solutions.

The successful clinical application of AI-based nanomedicine hinges on synchronized progress across several areas: the development of strong regulatory frameworks that support dynamic AI learning, the creation of extensive databases that facilitate model training across various diseases and diverse patient groups, advancements in manufacturing technologies that ensure consistent production quality, and the formulation of clinical trial designs suited to evolving therapeutic approaches. Engaging with regulatory authorities like the FDA and EMA early in the process is crucial, as programs such as the FDA’s Breakthrough Therapy Designation can accelerate access to innovative treatments. Collaborative initiatives among academic institutions, pharmaceutical companies, device manufacturers, and regulatory agencies will be vital to set benchmarks for the approval and ongoing monitoring of AI-driven nanomedicines. Currently, fewer than 5% of nanoscale therapies that proceed to phase I trials receive market approval, underscoring significant hurdles in demonstrating both clinical effectiveness and consistent manufacturing processes<sup>52,53,54</sup>.

### IV. CONCLUSION

The fusion of artificial intelligence and nanotechnology marks a significant advancement, offering remarkable possibilities for targeted medicine and individualized treatment strategies. By utilizing machine learning, deep learning, and sophisticated computational methodologies to innovate and refine nanoparticles, forecast safety profiles, tailor targeting methods, and facilitate adaptive real-time drug delivery, this combined discipline tackles key shortcomings inherent in traditional pharmaceutical methods. Notable achievements in treating cancer, neurological illnesses, preventing infections, and managing cardiovascular conditions highlight the transformative capacity of this technology to enhance healthcare delivery.

Yet, unlocking this potential comes with considerable hurdles, including the need for data standardization, improving model interpretability, developing regulatory frameworks, scaling manufacturing processes, ensuring long-term safety assessments, and implementing equitable clinical practices. To navigate these challenges, interdisciplinary teams of biomedical engineers, computer scientists, data analysts, healthcare professionals, and regulatory specialists must work together. The forthcoming decade is expected to accelerate the integration of AI-enhanced nanomedicines into clinical settings, particularly in oncology and rare genetic disorders where precise targeting provides distinct therapeutic benefits. Funding fundamental research, creating open-source datasets, enhancing computational resources, and aligning regulatory guidelines will be crucial for translating research advancements into practical health solutions for

patient populations worldwide. As these innovations advance and prove their clinical value, AI-guided nanotechnology will likely play a pivotal role in shaping the future of pharmaceutical development in the twenty-first century, fundamentally changing how therapeutic agents are discovered, designed, optimized, and administered to maximize treatment efficacy while minimizing side effects.

#### V. CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest related to this work. This review was prepared independently without any financial, commercial, or institutional influence. No funding or support was received for the preparation of this manuscript.

#### VI. ACKNOWLEDGMENT

The authors would like to extend their heartfelt thanks to all the mentors, colleagues, and academic supporters who offered indispensable guidance and motivation during the development of this review. They also recognize the valuable insights drawn from existing scholarly literature and scientific advancements in the field, which significantly enhanced the overall quality of this work.

#### REFERENCES

1. Christian P, Von der Kammer F, Baalousha M, Hofmann T. Nanoparticles: structure, properties, and preparation. *Environ Toxicol Chem.* 2008;27(9):1825–51.
2. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.* 2019;25:44–56.
3. Sharma A, Lee BK, Choi TG, et al. X-AI in nanomedicine: merging artificial intelligence with advanced nanotechnology for precision drug delivery. *Adv Drug Deliv Rev.* 2021;176:113–128.
4. Prasad P. The synergy of AI and nanotechnology in developing responsive drug delivery systems. *Int J Sci Res Eng Trends.* 2022;8(6):2454–6. Available from: <https://ijsret.com/wp-content/uploads/ijsret.vol.8.issue6.552.pdf>.
5. Jena GK, Patra CN, Jammula S, Rana R, Chand S. Artificial intelligence and machine learning implemented drug delivery systems: a paradigm shift in the pharmaceutical industry. *J Bio-X Res.* 2024;7:0016. Doi:10.34133/jbioXresearch.0016.
6. Noury H, Rahdar A, Romanholo Ferreira LF, Jamalpoor Z. AI-driven innovations in smart multifunctional nanocarriers for drug and gene delivery: a mini-review. *Crit Rev Oncol Hematol.* 2025 Jun;210:104701. Doi:10.1016/j.critrevonc.2025.104701. Epub 2025 Mar 13. PMID: 40086770.
7. Mody N, Tekade RK, Mehra NK, Chopdey P, Jain NK. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. *AAPS PharmSciTech.* 2014 Apr;15(2):388–99. Doi:10.1208/s12249-014-0073-3. Epub 2014 Jan 16. PMID: 24431104; PMCID: PMC3969491.
8. Rao TR, Sravani B, Aarthi R. Nanocarriers in drug delivery systems: an overview. *J Adv Sci Res.* 2025;16(03):8–14. Doi:10.55218/JASR.2025160302.
9. Mekki-Berrada F, Ren Z, Huang T, et al. Two-step machine learning enables optimized nanoparticle synthesis. *NPJ Comput Mater.* 2021;7:55. Available from: <https://doi.org/10.1038/s41524-021-00520-w>.
10. Vohra P, Chaudhari A, Shaikh F. Quantum dots as drug delivery vehicles: an abeyant leap in cancer therapy: quantum dots as potential drug carriers. *IJPSN.* 2024 Feb;17(1):7204–9. Available from: <https://www.ijpsnonline.com/index.php/ijpsn/article/view/3724>.
11. Bhurbhure O, Ghormade V, Katekar V, et al. Quantum dots: a new hope for the pharmaceutical field. *J Drug Deliv Ther.* 2022;12(3-S):236–44. Doi:10.22270/jddt.v12i3-s.5373.
12. Oliveres R. A comprehensive review of passive and active nanoparticle targeting technics. *Inside Therapeutics [Internet].* 2025 Oct 2 [cited 2025 Dec 12]. Available from: <https://insidetx.com/resources/reviews/a-comprehensive-review-of-passive-and-active-nanoparticle-targeting-technics/?utm>.
13. Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: a key facilitator for solid tumor targeting by nanoparticles. *Photodiagnosis Photodyn Ther.* 2022 Sep;39:102915. Doi:10.1016/j.pdpdt.2022.102915. Epub 2022 May 18. PMID: 35597441.
14. Bazak R, Houry M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. *Mol Clin Oncol.* 2014 Nov;2(6):904–8. Doi:10.3892/mco.2014.356. Epub 2014 Jul 23. PMID: 25279172; PMCID: PMC4179822.

15. Chen C, Zhong W, Du S, et al. Intelligent nanotherapeutic strategies for the delivery of CRISPR system. *Acta Pharm Sin B*. 2023 Jun;13(6):2510–43. Doi:10.1016/j.apsb.2022.12.013. Epub 2022 Dec 22. PMID: 37425051; PMCID: PMC10326264.
16. Pytlíková S, Konefař R, Pola R, et al. Polymer–drug conjugates with degradable oligo-(tetrahydrofuran) linkers for controlled drug release. *ACS Appl Bio Mater*. 2025;8(1):271–84. Doi:10.1021/acsbam.4c01167.
17. Farjadian F, Ghasemi S, Akbarian M, et al. Physically stimulus-responsive nanoparticles for therapy and diagnosis. *Front Chem*. 2022;10:952675. Doi:10.3389/fchem.2022.952675.
18. Das SS, Bharadwaj P, Bilal M, et al. Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. *Polymers (Basel)*. 2020 Jun 22;12(6):1397. Doi:10.3390/polym12061397. PMID: 32580366; PMCID: PMC7362228.
19. Chen X, Lv H. Intelligent control of nanoparticle synthesis on microfluidic chips with machine learning. *NPG Asia Mater*. 2022;14:69. Available from: <https://doi.org/10.1038/s41427-022-00416-1>.
20. Hidayat N. Predictive modeling of nanomaterial toxicity using machine learning. *Int J Sci Res Eng Trends*. 2022;8(6):2448–50. Available from: <https://ijsret.com/wp-content/uploads/ijsret.vol.8.issue6.550.pdf>.
21. Ahmadi M, Ayyoubzadeh SM, Ghorbani-Bidkorpheh F. Toxicity prediction of nanoparticles using machine learning approaches. *Toxicology*. 2024;501:153697. Doi:10.1016/j.tox.2023.153697.
22. Banaye Yazdipour A, Masoorian H, Ahmadi M, et al. Predicting the toxicity of nanoparticles using artificial intelligence tools: a systematic review. *Nanotoxicology*. 2023 Feb;17(1):62–77. Doi:10.1080/17435390.2023.2186279. Epub 2023 Mar 8. PMID: 36883698.
23. Xiao X, Trinh TX, Gerelkhuu Z, et al. Automated machine learning in nanotoxicity assessment: a comparative study of predictive model performance. *Comput Struct Biotechnol J*. 2024 Feb 9;25:9–19. Doi:10.1016/j.csbj.2024.02.003. PMID: 38414794; PMCID: PMC10899003.
24. Khakpour A, Florescu L, Tilley R, et al. AI-powered prediction of nanoparticle pharmacokinetics: a multi-view learning approach [preprint]. *arXiv [Internet]*. 2025 Mar 18 [cited 2025 Dec 12];arXiv:2503.13798. Available from: <https://arxiv.org/abs/2503.13798>. Doi:10.48550/arXiv.2503.13798.
25. Mavroudis PD, Teutonico D, Abos A, Pillai N. Application of machine learning in combination with mechanistic modeling to predict plasma exposure of small molecules. *Front Syst Biol*. 2023;3:1180948. Doi:10.3389/fsysb.2023.1180948.
26. Ortiz-Perez A, van Tilborg D, van der Meel R, et al. Machine learning-guided high throughput nanoparticle design. *Digit Discov*. 2024;3:1280–91. Doi:10.1039/D4DD00104D.
27. Saeed MM, Carthy E, Dunne N, Kinahan D. Advances in nanoparticle synthesis assisted by microfluidics. *Lab Chip*. 2025;25:3060–93. Doi:10.1039/D5LC00194C.
28. Tan P, Chen X, Zhang H, et al. Artificial intelligence aids in development of nanomedicines for cancer management. *Semin Cancer Biol*. 2023;89:61–75. Doi:10.1016/j.semcancer.2023.01.005.
29. Samathoti P, Kumarachari RK, Bukke SPN, et al. The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations—a narrative review. *Discov Oncol*. 2025 May 8;16(1):697. Doi:10.1007/s12672-025-02469-4. PMID: 40338421; PMCID: PMC12061837.
30. Jiménez A, Estudillo E, Guzmán-Ruiz MA, et al. Nanotechnology to overcome blood-brain barrier permeability and damage in neurodegenerative diseases. *Pharmaceutics*. 2025 Feb 20;17(3):281. Doi:10.3390/pharmaceutics17030281. PMID: 40142945; PMCID: PMC11945272.
31. Ljubimova JY, Holler E, Black KL, Ljubimov AV. Nanoparticles crossing blood-brain barrier need specific design for normal, neurodegenerative or cancerous brain conditions. *Nanomedicine (Lond)*. 2024;19(23):1863–6. Doi:10.1080/17435889.2024.2380241. Epub 2024 Aug 7. PMID: 39109486; PMCID: PMC11457639.
32. Aftab N, Masood F, Ahmad S, et al. An optimized deep learning approach for blood–brain barrier permeability prediction with ODE integration. *Informatics Med Unlocked*. 2024;48:101526. Doi:10.1016/j.imu.2024.101526.
33. Skwarek A, Gąsecka A, Jaguszewski MJ, et al. Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment. *Arch Med Sci*. 2021 Oct 15;19(5):1410–20. Doi:10.5114/aoms.142103. PMID: 37732058; PMCID: PMC10507787.
34. Vu MN, Kelly HG, Kent SJ, Wheatley AK. Current and future nanoparticle vaccines for COVID-19. *EBioMedicine*. 2021 Dec;74:103699. Doi:10.1016/j.ebiom.2021.103699. Epub 2021 Nov 19. PMID: 34801965; PMCID: PMC8602808.
35. Yu Y, Silva-Ayala D, Zhou Z, et al. Cellular nanoparticles treat coronavirus infection in vivo. *Nano Lett*. 2024;24(47):15136–41. Doi:10.1021/acsnanolett.4c04653.

36. Martín Giménez VM, Kassuha DE, Manucha W. Nanomedicine applied to cardiovascular diseases: latest developments. *Ther Adv Cardiovasc Dis.* 2017 Apr;11(4):133–42. Doi:10.1177/1753944717692293. Epub 2017 Feb 15. PMID: 28198204; PMCID: PMC5933544.
37. Gu X, Du L, Lin R, et al. How advanced is nanomedicine for atherosclerosis? *Int J Nanomedicine.* 2025;20:3445–70. Doi:10.2147/IJN.S508757.
38. Duan L, Ouyang K, Xu X, et al. Nanoparticle delivery of CRISPR/Cas9 for genome editing. *Front Genet.* 2021;12:673286. Doi:10.3389/fgene.2021.673286.
39. De Spirito M, Palmieri V, Perini G, Papi M. Bridging the gap: integrating 3D bioprinting and microfluidics for advanced multi-organ models in biomedical research. *Bioengineering (Basel).* 2024 Jun 28;11(7):664. Doi:10.3390/bioengineering11070664. PMID: 39061746; PMCID: PMC11274229.
40. Gimondi S, Ferreira H, Reis RL, Neves NM. Microfluidic devices: a tool for nanoparticle synthesis and performance evaluation. *ACS Nano.* 2023 Aug 8;17(15):14205–28. Doi:10.1021/acsnano.3c01117. Epub 2023 Jul 27. PMID: 37498731; PMCID: PMC10416572.
41. Zheng C, Li M, Ding J. Challenges and opportunities of nanomedicines in clinical translation. *BIO Integration.* 2021;2(2):57–60. Doi:10.15212/bioi-2021-0016. Available from: <https://bio-integration.org/>.
42. El-Fatyany A, Wang H, Abd El-Atty SM. Efficient framework analysis for targeted drug delivery based on Internet of Bio-NanoThings. *Arab J Sci Eng.* 2021;46(10):9965–80. Doi:10.1007/s13369-021-05651-2. Epub 2021 Apr 22. PMID: 33907662; PMCID: PMC8061466.
43. Akhtar N, Perwej Y. The internet of nano things (IoNT) existing state and future prospects. *GSC Adv Res Rev.* 2020;5(2):131–50. Doi:10.30574/gscarr.2020.5.2.0110.
44. Yang RX, McCandler CA, Andriuc O, et al. Big data in a nano world: a review on computational, data-driven design of nanomaterials structures, properties, and synthesis. *ACS Nano.* 2022;16(12):19873–91. Doi:10.1021/acsnano.2c08411.
45. Qadri YA, Shaikh S, Ahmad K, et al. Explainable artificial intelligence: a perspective on drug discovery. *Pharmaceutics.* 2025 Aug 27;17(9):1119. Doi:10.3390/pharmaceutics17091119. PMID: 41012456; PMCID: PMC12472777.
46. Răz T, Pahud De Mortanges A, Reyes M. Explainable AI in medicine: challenges of integrating XAI into the future clinical routine. *Front Radiol.* 2025 Aug 5;5:1627169. Doi:10.3389/fradi.2025.1627169. PMID: 40896521; PMCID: PMC12391920.
47. Muhammad D, Bendechache M. Unveiling the black box: a systematic review of explainable artificial intelligence in medical image analysis. *Comput Struct Biotechnol J.* 2024 Aug 12;24:542–60. Doi:10.1016/j.csbj.2024.08.005. PMID: 39252818; PMCID: PMC11382209.
48. Sivonxay E, Attia L, Spotte-Smith EWC, et al. Gradient-based optimization of complex nanoparticle heterostructures enabled by deep learning on heterogeneous graphs. *Nat Comput Sci.* 2025. Available from: <https://doi.org/10.1038/s43588-025-00917-3>.
49. Santra S, Kukreja P, Saxena K, et al. Navigating regulatory and policy challenges for AI enabled combination devices. *Front Med Technol.* 2024 Nov 28;6:1473350. Doi:10.3389/fmedt.2024.1473350. PMID: 39669903; PMCID: PMC11634576.
50. DIVERSA Technologies. Overcoming regulatory hurdles in clinical translation of nanomedicine [Internet]. DIVERSA Technologies; 2025 Feb 25 [cited 2025 Dec 12]. Available from: <https://www.diversatechnologies.com/overcoming-regulatory-hurdles-in-clinical-translation-of-nanomedicine/?utm>.
51. Rahman T, Tahmid A, Arman SE, et al. Leveraging generative neural networks for accurate, diverse, and robust nanoparticle design. *Nanoscale Adv.* 2024 Dec 9;7(2):634–42. Doi:10.1039/d4na00859f. PMID: 39659763; PMCID: PMC11627239.
52. Laubenbacher R, Niarakis A, Helikar T, et al. Building digital twins of the human immune system: toward a roadmap. *NPJ Digit Med.* 2022;5:64. Available from: <https://doi.org/10.1038/s41746-022-00610-z>.
53. Adhikari C, Das PK, Pramanik T. Digital twins for drug design: importance, applications and future perspectives. *Orient J Chem.* 2025;41(6). Available from: <https://bit.ly/47QvSin>.
54. Maharjan R, Kim NA, Kim KH, Jeong SH. Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives. *Int J Pharm X.* 2025;10:100409. Doi:10.1016/j.ijpx.2025.100409.



INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 9940 572 462  6381 907 438  [ijirset@gmail.com](mailto:ijirset@gmail.com)



[www.ijirset.com](http://www.ijirset.com)

Scan to save the contact details